source
- AstraZeneca signs $40 million AI drug-discovery deal with insitro as inVIOs reports Phase 1 tumor successAstraZeneca announced a partnership with insitro, a California AI‑driven drug discovery firm, agreeing to pay $40 million upfront for collaboration. The agreement aims to combine AstraZeneca’s the…
- FDA launches Rare Disease Framework Initiative to overhaul review processThe FDA announced a new Rare Disease Framework Initiative aimed at redesigning how therapies for rare conditions are regulated. The initiative will move away from a one-size-fits-all model, instea…